TOP TEN perturbations for 1519_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1519_at
Selected probe(set): 201328_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1519_at (201328_at) across 6540 perturbations tested by GENEVESTIGATOR:
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-4.320383Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Relative Expression (log2-ratio):3.6950245Number of Samples:2 / 9
Experimental | expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin. | |
Control | expO skin cancer study 1 (malignant melanoma, NOS; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin. |
breast cancer study 5 / normal organelle sample
Relative Expression (log2-ratio):-3.5535145Number of Samples:20 / 12
Experimental | breast cancer study 5 |
Breast non-BLC (sporadic basal-like cancer) tumor samples. | |
Control | normal organelle sample |
Normal organelle samples. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.5351753Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample
Relative Expression (log2-ratio):-3.466363Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal myeloid dendritic cell sample |
Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):-3.4306297Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)
Relative Expression (log2-ratio):3.4209185Number of Samples:10 / 10
Experimental | ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 |
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:--- | |
Control | ZSTK474 study 1 (10uM) |
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:--- |
ALL study 3 (8d) / ALL study 3 (0d)
Relative Expression (log2-ratio):-3.4168034Number of Samples:2 / 2
Experimental | ALL study 3 (8d) |
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken 8 days after remission-induction therapy (RIT). | |
Control | ALL study 3 (0d) |
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT). |
OPM-1 / MM1.S
Relative Expression (log2-ratio):3.316657Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.2371073Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |